After no response to warnings, Pfizer sought an preliminary injunction in the Makati Trial Court in 2008. This was refused for somewhat spurious reasons. Sahar argued the patents were expiring overseas, and its foreign sourced products could thus be sold. The preliminary injunction was the subject of the appeal by Pfizer to the Court of Appeal which granted it.
Then in 2014 the Supreme Court heard Sahar's appeal. It said the injunction was properly granted, the Court of Appeal had found patent infringement and so the Supreme Court made the injunction permanent, awarded both 8,000 USD in damages USD and 1200 exemplary damages and also an award for fees and litigation expenses. It also confirmed the seizure of Sahar’s ATOPITAR.